Skip to content

Understanding Tick-borne Diseases

One-Health Approach to Identify Threat Posed by Tick-borne Pathogens Responsible of Unexplained Infectious Syndrome in Humans

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03501407
Acronym
OHTICKS
Enrollment
130
Registered
2018-04-18
Start date
2018-06-01
Completion date
2020-06-30
Last updated
2018-08-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lyme Disease

Brief summary

Ticks are the major arthropod vectors transmitting pathogenic agents to humans and domestic animals in Europe, and currently, the incidence of tick-borne disease is rising. The most common European human tick-borne disease is Lyme borreliosis, with an estimated 90 000 new cases every year (compared to 300 000 new cases in the United States annually). This disease is initially clinically diagnosed by the presence of migrating erythema following a tick bite, which is then subsequently confirmed by serological tests. In parallel with classic Lyme borreliosis cases, tick-bitten patients can also present with polymorphic and on-specific clinical symptoms (asthenia, fever, myalgia, etc. …) for which there is no known etiological diagnosis. It is extremely difficult to determine the proportion of tick-bitten patients with these symptoms compared to patients which have actually contracted Lyme disease, although it is estimated that 50% of fevers following a tick bite have an unknown infectious origin. Typical tick habitats are woodlands, prairies, pastures, and gardens. Ticks are extremely sensitive to environmental fluctuations, which are often brought about by human socio-economic changes, thus tick-borne diseases are excellent candidates for emergence. Consequently, it is incontestable that tickborne diseases pose a significant threat to our society. In addition to improving diagnostic techniques, one of the major hurdles relates to improving public and health professional knowledge about tick disease risk. The battle against tick-borne diseases is based on relatively simple prevention measures, and their effectiveness is immeasurably improved when citizens are more informed and involved.Therefore, a multidisciplinary project, bringing together veterinarians, doctors, scientists, and consultant sociologists has been designed to create a global One Health approach to tick-borne diseases. Specific scientific project objectives are to (1) detect, identify, and isolate new microorganisms-both unknown or unexpected-from patients or animals suffering from unexplainable symptoms following tick bites; (2) to demonstrate tick competence in their ability to transmit these agents; and (3) to generate concrete recommendations to improve tick-borne disease management.

Interventions

DIAGNOSTIC_TESTBlood samples

1 or 2 blood samples will be collected from the patient.

DIAGNOSTIC_TESTskin biopsy

A skin biopsy will be performed on the periphery of the erythema migrans

Sponsors

Institut Pasteur
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

for patient with an erythema migrans * Age≥18 years * Erythema migrans * Registered with social security * informed and written consent

Exclusion criteria

for patient with an erythema migrans * Pregnant women * Immunocompromised patients (undergoing chemotherapy, corticotherapy, or biotherapy) * Chronic inflammatory disease * Systemic disease Inclusion Criteria for patient with no-erythema migrans: * Age≥18 years * Confirmed tick bite within the last 6 months prior to the appearance of inflammatory joint disease verified via joint imaging (MRI or ultrasound) * and/or cerebrospinal fluid cyto-chemical anomalies (meningitis,albuminocytological dissociation) * Registered with social security * informed and written consent

Design outcomes

Primary

MeasureTime frame
Isolate new microorganisms-both unknown or unexpected-from patients suffering from unexplainable symptoms following tick bitesup to 12 months

Countries

France

Contacts

Primary Contactcecile Artaud
cecile.artaud@pasteur.fr+33144389241
Backup ContactMuriel Vayssier, PhD

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026